Use: Labeled indications
- INDICATIONS AND USAGE For the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency.
Full indications and usage US FDA label
INDICATIONS AND USAGE For the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency. For the prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.
Contraindications
CONTRAINDICATIONS None known.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION CARNITOR ® Injection is administered intravenously. Metabolic Disorders The recommended dose is 50 mg/kg given as a slow 2-3 minute bolus injection or by infusion. Often a loading dose is given in patients with severe metabolic crisis, followed by an equivalent dose over the following 24 hours. It should be administered q3h or q4h, and never less than q6h either by infusion or by intravenous injection.
All subsequent daily doses are recommended to be in the range of 50 mg/kg or as therapy may require. The highest dose administered has been 300 mg/kg. It is recommended that a plasma carnitine concentration be obtained prior to beginning this parenteral therapy. Weekly and monthly monitoring is recommended as well. This monitoring should include blood chemistries, vital signs, plasma carnitine concentrations (the plasma free carnitine concentration should be between 35 and 60 µmol/L) and overall clinical condition.
ESRD Patients on Hemodialysis The recommended starting dose is 10-20 mg/kg dry body weight as a slow 2-3 minute bolus injection into the venous return line after each dialysis session. Initiation of therapy may be prompted by trough (pre-dialysis) plasma levocarnitine concentrations that are below normal (40-50 µmol/L).
Dose adjustments should be guided by trough (pre-dialysis) levocarnitine concentrations, and downward dose adjustments (e.g. to 5 mg/kg after dialysis) may be made as early as the third or fourth week of therapy. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Dosing: Altered kidney function
Renal Disease (ESRD) patients on maintenance hemodialysis may have low plasma carnitine concentrations and an increased ratio of acylcarnitine/carnitine because of reduced intake of meat and dairy products, reduced renal synthesis and dialytic losses. Certain clinical conditions common in hemodialysis patients such as malaise, muscle weakness, cardiomyopathy and cardiac arrhythmias may be related to abnormal carnitine metabolism.
Pharmacokinetic and clinical studies with CARNITOR ® have shown that administration of levocarnitine to ESRD patients on hemodialysis results in increased plasma levocarnitine concentrations.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use See Dosage and Administration.
Dosage forms
Philippines
- ) solution for injection: 200 mg/mL (1 g/5 mL, 200 mg/mL (1000 mg/5 mL
- Oral solution: 1 g/10 mL
Registered products in the Philippines
3 products registered with the Food and Drug Administration (FDA) Philippines list Levocarnitine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products3
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
LecarnitaLevocarnitine | 200 mg/mL (1000 mg/5 mL) Solution for Injection (I.V.)USP Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Help S.A.Greece | First Global Trading CorporationTrader: Perrery International Ltd. | DRP–12209 | Jun 30, 2027 | |
LevocarnilLevocarnitine | 200 mg/mL (1 g/5 mL) Solution for Injection (IV)Clear glass ampoule x 5 mL (Box of 5's) | Rx | Farbe Firma Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-14808 | Mar 6, 2029 | |
MetacartinLevocarnitine | 1 g /10 mL Oral SolutionIn 15 mL - capacity Type III amber glass colored vial x 10 mL (Box of 1's) | Rx | World Medicine Ilac Sanayi Ve Ticaret A.S.Turkey | Ambicare Pharmaceuticals Inc. | DRP-15158 | Jul 2, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylaxis, laryngeal edema, and bronchospasm have been reported following CARNITOR ® administration, mostly in patients with end stage renal disease who are undergoing dialysis. Some reactions occurred within minutes after intravenous administration of CARNITOR ®.
If a severe hypersensitivity reaction occurs, discontinue CARNITOR ® treatment and initiate appropriate medical treatment. Consider the risks and benefits of re-administering CARNITOR ® to individual patients following a severe reaction. If the decision is made to re-administer the product, monitor patients for a reoccurrence of signs and symptoms of a severe hypersensitivity reaction.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions Reports of INR increase with the use of warfarin have been observed. It is recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with levocarnitine or after dose adjustments.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Clinical Trials Experience Transient nausea and vomiting have been observed. Less frequent adverse reactions are body odor, nausea, and gastritis. An incidence for these reactions is difficult to estimate due to the confounding effects of the underlying pathology. The table below lists the adverse events that have been reported in two double-blind, placebo-controlled trials in patients on chronic hemodialysis.
Events occurring at ≥5% are reported without regard to causality. Adverse Events with a Frequency ≥5% Regardless of Causality by Body System Placebo (n=63) Levocarnitine 10 mg (n=34) Levocarnitine 20 mg (n=62) Levocarnitine 40 mg (n=34) Levocarnitine 10, 20 & 40 mg (n=130) Body as Whole Abdominal pain 17 21 5 6 9 Accidental injury 10 12 8 12 10 Allergic reaction 5 6 2 Asthenia 8 9 8 12 9 Back pain 10 9 8 6 8 Chest pain 14 6 15 12 12 Fever 5 6 5 12 7 Flu syndrome 40 15 27 29 25 Headache 16 12 37 3 22 Infection 17 15 10 24 15 Injection site reaction 59 38 27 38 33 Pain 49 21 32 35 30 Cardiovascular Arrhythmia 5 3 3 2 Atrial fibrillation 2 6 2 Cardiovascular disorder 6 3 5 6 5 Electrocardiogram abnormal 3 6 2 Hemorrhage 6 9 2 3 4 Hypertension 14 18 21 21 20 Hypotension 19 15 19 3 14 Palpitations 3 8 5 Tachycardia 5 6 5 9 6 Vascular disorder 2 2 6 2 Digestive Anorexia 3 3 5 6 5 Constipation 6 3 3 3 3 Diarrhea 19 9 10 35 16 Dyspepsia 10 9 6 5 Gastrointestinal disorder 2 3 6 2 Melena 3 6 2 Nausea 10 9 5 12 8 Stomach atony 5 Vomiting 16 9 16 21 15 Endocrine System Parathyroid disorder 2 6 2 6 4 Hemic/Lymphatic Anemia 3 3 5 12 6 Metabolic/Nutritional Hypercalcemia 3 15 8 6 9 Hyperkalemia 6 6 6 6 6 Hypervolemia 17 3 3 12 5 Peripheral edema 3 6 5 3 5 Weight decrease 3 3 8 3 5 Weight increase 2 3 6 2 Musculo-Skeletal Leg cramps 13 8 4 Myalgia 6 Nervous Anxiety 5 2 1 Depression 3 6 5 6 5 Dizziness 11 18 10 15 13 Drug dependence 2 6 2 Hypertonia 5 3 1 Insomnia 6 3 6 4 Paresthesia 3 3 3 12 5 Vertigo 6 2 Respiratory Bronchitis 5 3 3 Cough increase 16 10 18 9 Dyspnea 19 3 11 3 7 Pharyngitis 33 24 27 15 23 Respiratory disorder 5 Rhinitis 10 6 11 6 9 Sinusitis 5 2 3 2 Skin And Appendages Pruritus 13 8 3 5 Rash 3 5 3 3 Special Senses Amblyopia 2 6 3 Eye disorder 3 6 3 3 Taste perversion 2 9 3 Urogenital Urinary tract infect 6 3 3 2 Kidney failure 5 6 6 6 6 Postmarketing Experience The following adverse reactions have been reported: Neurologic Reactions: Seizures have been reported to occur in patients, with or without pre-existing seizure activity, receiving either oral or intravenous levocarnitine.
In patients with pre-existing seizure activity, an increase in seizure frequency and/or severity has been reported. Hypersensitivity reactions: Anaphylaxis, laryngeal edema and bronchospasm (see WARNINGS).
Adverse reaction frequency tables (US label) US FDA label
| Placebo (n=63) | Levocarnitine 10 mg (n=34) | Levocarnitine 20 mg (n=62) | Levocarnitine 40 mg (n=34) | Levocarnitine 10, 20 & 40 mg (n=130) | |
| Body as Whole | |||||
| Abdominal pain | 17 | 21 | 5 | 6 | 9 |
| Accidental injury | 10 | 12 | 8 | 12 | 10 |
| Allergic reaction | 5 | 6 | 2 | ||
| Asthenia | 8 | 9 | 8 | 12 | 9 |
| Back pain | 10 | 9 | 8 | 6 | 8 |
| Chest pain | 14 | 6 | 15 | 12 | 12 |
| Fever | 5 | 6 | 5 | 12 | 7 |
| Flu syndrome | 40 | 15 | 27 | 29 | 25 |
| Headache | 16 | 12 | 37 | 3 | 22 |
| Infection | 17 | 15 | 10 | 24 | 15 |
| Injection site reaction | 59 | 38 | 27 | 38 | 33 |
| Pain | 49 | 21 | 32 | 35 | 30 |
| Cardiovascular | |||||
| Arrhythmia | 5 | 3 | 3 | 2 | |
| Atrial fibrillation | 2 | 6 | 2 | ||
| Cardiovascular disorder | 6 | 3 | 5 | 6 | 5 |
| Electrocardiogram abnormal | 3 | 6 | 2 | ||
| Hemorrhage | 6 | 9 | 2 | 3 | 4 |
| Hypertension | 14 | 18 | 21 | 21 | 20 |
| Hypotension | 19 | 15 | 19 | 3 | 14 |
| Palpitations | 3 | 8 | 5 | ||
| Tachycardia | 5 | 6 | 5 | 9 | 6 |
| Vascular disorder | 2 | 2 | 6 | 2 | |
| Digestive | |||||
| Anorexia | 3 | 3 | 5 | 6 | 5 |
| Constipation | 6 | 3 | 3 | 3 | 3 |
| Diarrhea | 19 | 9 | 10 | 35 | 16 |
| Dyspepsia | 10 | 9 | 6 | 5 | |
| Gastrointestinal disorder | 2 | 3 | 6 | 2 | |
| Melena | 3 | 6 | 2 | ||
| Nausea | 10 | 9 | 5 | 12 | 8 |
| Stomach atony | 5 | ||||
| Vomiting | 16 | 9 | 16 | 21 | 15 |
| Endocrine System | |||||
| Parathyroid disorder | 2 | 6 | 2 | 6 | 4 |
| Hemic/Lymphatic | |||||
| Anemia | 3 | 3 | 5 | 12 | 6 |
| Metabolic/Nutritional | |||||
| Hypercalcemia | 3 | 15 | 8 | 6 | 9 |
| Hyperkalemia | 6 | 6 | 6 | 6 | 6 |
| Hypervolemia | 17 | 3 | 3 | 12 | 5 |
| Peripheral edema | 3 | 6 | 5 | 3 | 5 |
| Weight decrease | 3 | 3 | 8 | 3 | 5 |
| Weight increase | 2 | 3 | 6 | 2 | |
| Musculo-Skeletal | |||||
| Leg cramps | 13 | 8 | 4 | ||
| Myalgia | 6 | ||||
| Nervous | |||||
| Anxiety | 5 | 2 | 1 | ||
| Depression | 3 | 6 | 5 | 6 | 5 |
| Dizziness | 11 | 18 | 10 | 15 | 13 |
| Drug dependence | 2 | 6 | 2 | ||
| Hypertonia | 5 | 3 | 1 | ||
| Insomnia | 6 | 3 | 6 | 4 | |
| Paresthesia | 3 | 3 | 3 | 12 | 5 |
| Vertigo | 6 | 2 | |||
| Respiratory | |||||
| Bronchitis | 5 | 3 | 3 | ||
| Cough increase | 16 | 10 | 18 | 9 | |
| Dyspnea | 19 | 3 | 11 | 3 | 7 |
| Pharyngitis | 33 | 24 | 27 | 15 | 23 |
| Respiratory disorder | 5 | ||||
| Rhinitis | 10 | 6 | 11 | 6 | 9 |
| Sinusitis | 5 | 2 | 3 | 2 | |
| Skin And Appendages | |||||
| Pruritus | 13 | 8 | 3 | 5 | |
| Rash | 3 | 5 | 3 | 3 | |
| Special Senses | |||||
| Amblyopia | 2 | 6 | 3 | ||
| Eye disorder | 3 | 6 | 3 | 3 | |
| Taste perversion | 2 | 9 | 3 | ||
| Urogenital | |||||
| Urinary tract infect | 6 | 3 | 3 | 2 | |
| Kidney failure | 5 | 6 | 6 | 6 | 6 |
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Reproductive studies have been performed in rats and rabbits at doses up to 3.8 times the human dose on the basis of surface area and have revealed no evidence of impaired fertility or harm to the fetus due to CARNITOR ®. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Levocarnitine supplementation in nursing mothers has not been specifically studied. Studies in dairy cows indicate that the concentration of levocarnitine in milk is increased following exogenous administration of levocarnitine. In nursing mothers receiving levocarnitine, any risks to the child of excess carnitine intake need to be weighed against the benefits of levocarnitine supplementation to the mother. Consideration may be given to discontinuation of nursing or of levocarnitine treatment.
Pharmacokinetics
Following a single i.v. administration, approximately 76% of the levocarnitine dose was excreted in the urine during the 0-24h interval.
Using plasma concentrations uncorrected for endogenous levocarnitine, the mean distribution half life was 0.585 hours and the mean apparent terminal elimination half life was 17.4 hours.
Pharmacokinetics (US label) US FDA label
PHARMACOKINETICS In a relative bioavailability study in 15 healthy adult male volunteers, CARNITOR ® Tablets were found to be bio-equivalent to CARNITOR ® Oral Solution. Following 4 days of dosing with 6 tablets of CARNITOR ® 330 mg b.i.d. or 2 g of CARNITOR ® oral solution b.i.d., the maximum plasma concentration (C max) was about 80 µmol/L and the time to maximum plasma concentration (T max) occurred at 3.3 hours.
The plasma concentration profiles of levocarnitine after a slow 3 minute intravenous bolus dose of 20 mg/kg of CARNITOR ® were described by a two-compartment model. Following a single i.v. administration, approximately 76% of the levocarnitine dose was excreted in the urine during the 0-24h interval. Using plasma concentrations uncorrected for endogenous levocarnitine, the mean distribution half life was 0.585 hours and the mean apparent terminal elimination half life was 17.4 hours.
The absolute bioavailability of levocarnitine from the two oral formulations of CARNITOR ®, calculated after correction for circulating endogenous plasma concentrations of levocarnitine, was 15.1 ± 5.3% for CARNITOR ® Tablets and 15.9 ± 4.9% for CARNITOR ® Oral Solution. Total body clearance of levocarnitine (Dose/AUC including endogenous baseline concentrations) was a mean of 4.00 L/h.
Levocarnitine was not bound to plasma protein or albumin when tested at any concentration or with any species including the human. 9 In a 9-week study, 12 ESRD patients undergoing hemodialysis for at least 6 months received CARNITOR ® 20 mg/kg three times per week after dialysis. Prior to initiation of CARNITOR ® therapy, mean plasma levocarnitine concentrations were approximately 20 µmol/L pre-dialysis and 6 µmol/L post-dialysis.
The table summarizes the pharmacokinetic data (mean ± SD µmol/L) after the first dose of CARNITOR ® and after 8 weeks of CARNITOR ® therapy. N=12 Baseline Single dose 8 weeks C max - 1139 ± 240 1190 ± 270 Trough (pre-dialysis, pre-dose) 21.3 ± 7.7 68.4 ± 26.1 190 ± 55 After one week of CARNITOR ® therapy (3 doses), all patients had trough concentrations between 54 and 180 µmol/L (normal 40-50 µmol/L) and concentrations remained relatively stable or increased over the course of the study.
In a similar study in ESRD patients also receiving 20 mg/kg CARNITOR ® 3 times per week after hemodialysis, 12- and 24-week mean pre-dialysis (trough) levocarnitine concentrations were 189 (N=25) and 243 (N=23) µmol/L, respectively. In a dose-ranging study in ESRD patients undergoing hemodialysis, patients received 10, 20, or 40 mg/kg CARNITOR ® 3 times per week following dialysis (N~30 for each dose group).
Mean ± SD trough levocarnitine concentrations (µmol/L) by dose after 12 and 24 weeks of therapy are summarized in the table. 12 weeks 24 weeks 10 mg/kg 116 ± 69 148 ± 50 20 mg/kg 210 ± 58 240 ± 60 40 mg/kg 371 ± 111 456 ± 162 While the efficacy of CARNITOR ® to increase carnitine concentrations in patients with ESRD undergoing dialysis has been demonstrated, the effects of supplemental carnitine on the signs and symptoms of carnitine deficiency and on clinical outcomes in this population have not been determined.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Carnitor · Leadiant Biosciences, Inc. [US FDA-approved label, version 19, November 20, 2023]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf801cc4-775e-433d-9d32-e5d9a98981d3
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .